Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprot...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2022/8129513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685934764720128 |
|---|---|
| author | Iveta Merćep Nikolina Friščić Dominik Strikić Željko Reiner |
| author_facet | Iveta Merćep Nikolina Friščić Dominik Strikić Željko Reiner |
| author_sort | Iveta Merćep |
| collection | DOAJ |
| description | As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and small interfering RNA- (siRNA-) based drug targeting PCSK9 represent a new strategy for managing lipid disorders and reducing cardiovascular risk. Inclisiran is a long-acting, synthetic siRNA that targets hepatic production of PCSK9 and consequently causes a reduction in LDL-C concentrations by approximately 50% compared to placebo. The structural modification of inclisiran has led to better stability and prolonged biological activity of the drug. The main advantage over conventional pharmacotherapy and anti-PCSK9 monoclonal antibodies is its favorable administration regimen (0–90–180 days), which should lead to much better compliance. Clinical trials conducted so far have confirmed the tolerability and efficacy of inclisiran in long-term PCSK9 and LDL-C level reductions. Moreover, a short-term follow-up on the safety of inclisiran showed a relatively good safety profile of the drug. However, it is still of great importance for ongoing and forthcoming clinical trials to be continued on a larger group of patients in order to assess long-term tolerability, efficacy, and safety of inclisiran. |
| format | Article |
| id | doaj-art-bba37d73a22040bf8e933a5ac92c20e4 |
| institution | DOAJ |
| issn | 1755-5922 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-bba37d73a22040bf8e933a5ac92c20e42025-08-20T03:22:54ZengWileyCardiovascular Therapeutics1755-59222022-01-01202210.1155/2022/8129513Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative ReviewIveta Merćep0Nikolina Friščić1Dominik Strikić2Željko Reiner3Department of Clinical PharmacologyResident of the Transfusion MedicineResident of the Clinical PharmacologyDepartment of Internal MedicineAs dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and small interfering RNA- (siRNA-) based drug targeting PCSK9 represent a new strategy for managing lipid disorders and reducing cardiovascular risk. Inclisiran is a long-acting, synthetic siRNA that targets hepatic production of PCSK9 and consequently causes a reduction in LDL-C concentrations by approximately 50% compared to placebo. The structural modification of inclisiran has led to better stability and prolonged biological activity of the drug. The main advantage over conventional pharmacotherapy and anti-PCSK9 monoclonal antibodies is its favorable administration regimen (0–90–180 days), which should lead to much better compliance. Clinical trials conducted so far have confirmed the tolerability and efficacy of inclisiran in long-term PCSK9 and LDL-C level reductions. Moreover, a short-term follow-up on the safety of inclisiran showed a relatively good safety profile of the drug. However, it is still of great importance for ongoing and forthcoming clinical trials to be continued on a larger group of patients in order to assess long-term tolerability, efficacy, and safety of inclisiran.http://dx.doi.org/10.1155/2022/8129513 |
| spellingShingle | Iveta Merćep Nikolina Friščić Dominik Strikić Željko Reiner Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review Cardiovascular Therapeutics |
| title | Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review |
| title_full | Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review |
| title_fullStr | Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review |
| title_full_unstemmed | Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review |
| title_short | Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review |
| title_sort | advantages and disadvantages of inclisiran a small interfering ribonucleic acid molecule targeting pcsk9 a narrative review |
| url | http://dx.doi.org/10.1155/2022/8129513 |
| work_keys_str_mv | AT ivetamercep advantagesanddisadvantagesofinclisiranasmallinterferingribonucleicacidmoleculetargetingpcsk9anarrativereview AT nikolinafriscic advantagesanddisadvantagesofinclisiranasmallinterferingribonucleicacidmoleculetargetingpcsk9anarrativereview AT dominikstrikic advantagesanddisadvantagesofinclisiranasmallinterferingribonucleicacidmoleculetargetingpcsk9anarrativereview AT zeljkoreiner advantagesanddisadvantagesofinclisiranasmallinterferingribonucleicacidmoleculetargetingpcsk9anarrativereview |